The U.S. Food and Drug Administration on Thursday authorized the sale of the country’s best-selling e-cigarette. The agency’s decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse. In January 2023, the FDA rejected R.J. Reynold’s application for its more popular menthol flavor, but the company has challenged that ruling in court. Last month, the FDA granted competitor Njoy the first authorization for a menthol-flavored e-cigarette. That vaping brand is controlled by tobacco giant Altria. Despite the Vuse authorization, the FDA stressed that e-cigarettes are far from safe. “All tobacco products are harmful and potentially addictive,” the agency said in a new release announcing the decision. “Those who do not use tobacco products, especially young people, should not start.” In its decision, the agency noted that tobacco-flavored e-cigarettes do not hold the same appeal among youth that fruit- and candy-flavored vaping products do. “While FDA remains concerned about the risk of youth use of all e-cigarettes, youth are less likely to use tobacco‐flavored e-cigarette products compared to other flavors,” the agency said. “According to the 2023 National Youth Tobacco Survey, Vuse was among the most commonly reported brands used by middle and high school students currently using e-cigarette. However, only 6.4% of students who currently used e-cigarettes reported using tobacco‐flavored products.” To further discourage vaping among teens and adolescents, the FDA added that it… read on > read on >







